The company reported a 23.5% year-on-year decline in net profit, which came in at ₹518 crore compared with ₹677.3 crore in the same period last year.
Revenue for the quarter dipped slightly to ₹1,363 crore from ₹1,371 crore a year ago.
EBITDA also saw a sharp drop of 28%, falling to ₹579 crore versus ₹804 crore last year.
Consequently, the EBITDA margin narrowed to 42.5% from 58.6% year-on-year.
The board declared an interim dividend of ₹1.50 per equity share of face value ₹2 for the financial year 2025-26.
The record date for the dividend has been set as November 20, 2025, and payments will begin from November 28.
Shares of Natco Pharma Ltd. are trading 2% lower at ₹810. The stock has declined more than 40% so far in 2025.
/images/ppid_59c68470-image-176311002937591617.webp)

/images/ppid_59c68470-image-176310502606072898.webp)
/images/ppid_59c68470-image-176292763480036487.webp)
/images/ppid_59c68470-image-176291753096517578.webp)
/images/ppid_59c68470-image-176292010128080910.webp)
/images/ppid_59c68470-image-176285508663949616.webp)
/images/ppid_59c68470-image-176295758469496795.webp)
/images/ppid_59c68470-image-176286009089192897.webp)
/images/ppid_59c68470-image-176296254058314600.webp)
/images/ppid_59c68470-image-17629275338045946.webp)
/images/ppid_59c68470-image-176292027896990527.webp)